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Identification of Specific Proteins and Peptides in
Mycobacterium leprae Suitable for the Selective Diagnosis
of Leprosy1
John S. Spencer,2* Hazel M. Dockrell,† Hee Jin Kim,* Maria A. M. Marques,*
Diana L. Williams,‡ Marcia V. S. B. Martins,§** Marcio L. F. Martins,§ Monica C. B. S. Lima,§
Euzenir N. Sarno,¶ Geraldo M. B. Pereira,§ Haroldo Matos,# Leila S. Fonseca,**
Elisabeth P. Sampaio,¶ Thomas H. M. Ottenhoff,†† Annemieke Geluk,†† Sang-Nae Cho,‡‡
Neil G. Stoker,§§ Stewart T. Cole,¶¶ Patrick J. Brennan,* and Maria C. V. Pessolani§
Diagnosis of leprosy is a major obstacle to disease control and has been compromised in the past due to the lack of specific reagents.
We have used comparative genome analysis to identify genes that are specific to Mycobacterium leprae and tested both recombinant
proteins and synthetic peptides from a subset of these for immunological reactivity. Four unique recombinant proteins (ML0008,
ML0126, ML1057, and ML2567) and a panel of 58 peptides (15 and 9 mer) were tested for IFN- responses in PBMC from leprosy
patients and contacts, tuberculosis patients, and endemic and nonendemic controls. The responses to the four recombinant
proteins gave higher levels of IFN- production, but less specificity, than the peptides. Thirty-five peptides showed IFN- re-
sponses only in the paucibacillary leprosy and household contact groups, with no responses in the tuberculosis or endemic control
groups. High frequencies of IFN--producing CD4 and CD8 T cells specific for the 15- and 9-mer peptides were observed in
the blood of a paucibacillary leprosy patient. 9-mer peptides preferentially activated CD8 T cells, while the 15-mer peptides were
efficient in inducing responses in both the CD4 and CD8 T cell subsets. Four of the six 9-mer peptides tested showed promising
specificity, indicating that CD8 T cell epitopes may also have diagnostic potential. Those peptides that provide specific responses
in leprosy patients from an endemic setting could potentially be developed into a rapid diagnostic test for the early detection of
M. leprae infection and epidemiological surveys of the incidence of leprosy, of which little is known. The Journal of Immunology,
2005, 175: 7930–7938.
T he prevalence of leprosy worldwide has been reduced dra-matically, mainly through global coverage of multidrugtherapy, from 10 million cases in 1985 to 514,000
registered cases in 2003. New cases remain obstinately high in
many parts of the world (1–3). In the absence of appropriate tests,
we know little of the global incidence of leprosy. Diagnosis of the
disease is still based largely on clinical symptoms, which can be
verified by confirming the presence of acid-fast bacilli in suspected
lesions, an approach not widely practiced in leprosy control set-
tings. The single greatest need from leprosy research remains the
development of relatively simple diagnostic tools that could rap-
idly detect early infection and therefore underlying disease and
allow interventions before the onset of clinical symptoms.
Certain tests have been used in the past with varying degrees of
success. The finding of the leprosy-specific Ag, phenolic glyco-
lipid-I, has been exploited by ELISA for the presence of phenolic
glycolipid-I-specific Abs (4–6), as these Abs are present in high
titers in multibacillary (MB)3 leprosy patients. However, the Ab
titer is generally low or absent in paucibacillary (PB) patients.
Other diagnostic tests based on cell mediated immunity against
leprosy-specific protein Ags have been investigated, foremost
among them the IFN- whole blood assay, or a simple delayed-
type hypersensitivity skin test response, analogous to the purified
protein derivative (PPD) test used for tuberculosis (TB) (7). Be-
cause prior immunization with Mycobacterium bovis bacillus
Calmette-Gue´rin (BCG) and exposure to environmental mycobac-
teria are hurdles that must be overcome in the development of any
protein- or peptide-based diagnostic test, we were hopeful that the
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recent information provided by comparative mycobacterial
genomics (8, 9) will allow the development of Ags that are highly
specific for leprosy.
Through comparative analyses of these annotated genomes and
comparing with sequences from environmental mycobacteria, we
have selected putative open reading frames found only in the My-
cobacterium leprae genome, with no homologues in any of the
current mycobacterial databases. We have conducted preliminary
studies on four of these unique Ags to determine whether any are
potentially useful in the development of a specific test for the early
diagnosis of leprosy. In addition to the whole recombinant pro-
teins, peptides selected from 26 M. leprae open reading frames
predicted as having high scores for binding to human class II
HLA-DR or class I molecules were synthesized. This article char-
acterizes the IFN- responses of PBMC from leprosy and TB pa-
tients, contacts, and controls toward these proteins and peptides.
Materials and Methods
Selection of M. leprae genes and peptides
Comparative bioinformatic analyses of the M. leprae and Mycobacterium
tuberculosis genomes using various programs developed by Drs. N. G.
Stoker and S. T. Cole were used to generate lists of M. leprae genes that
were not present in M. tuberculosis, or in other mycobacteria using se-
quence information available at that time, and that appeared likely to be
expressed genes. M. leprae-predicted proteins (ftp://ftp.sanger.ac.uk/pub/
pathogens/leprae/) were compared with six-frame translations of other
mycobacterial genomes, both finished (M. tuberculosis) and unfinished
(Mycobacterium avium and Mycobacterium smegmatis), using TBLASTN
from National Center for Biotechnology Information basic local alignment
search tool (BLAST) (version 2.0) (10). Preliminary sequence data for M.
avium and M. smegmatis were obtained online from The Institute for
Genomic Research web site (www.tigr.org). Protein sequences were also
used to search a nonredundant protein library from GenBank using protein-
protein BLAST (BLASTP). Searches were run on May 17, 2001. All se-
quences finding a match with a value of e 0.01 were discarded. Using the
lists generated by these methods, we selected putative open reading frames
to target for recombinant protein production. The selected open reading
frames were screened subsequently for homologies with the genome se-
quences of M. marinum (www.sanger.ac.uk/Projects/M_marinum) or M.
avium and M. smegmatis (www.tigr.org/tdb/mdb/mdbinprotgress.html).
Peptide sequences (15 or 9 mer) were selected as having high scores for
binding to human class II HLA-DR (DRB1*0101, DRB1*0301 (DR17),
DRB1*0401 (DR4w4), and DRB1*1101) or human class I (HLA-A*0201)
using the SYFPEITHI program (www.bmi-heidelberg.com/syfpeithi).
All of the peptides were then screened for homologies to sequences in other
proteins by BLASTP using a program suitable for BLAST searches for
short nearly exact matches (www.ncbi.nlm.nih.gov/BLAST). Peptides
with significant degrees of homology to genes expressed in other potential
human pathogenic microorganisms to which T cell sensitization might be
expected (e.g., Streptococcus sp., Haemophilus influenzae) were excluded.
The peptides used in this study were synthesized commercially (Mimo-
topes), with a free amino and carboxy terminus, in 1 mmol scale. Each was
dissolved in endotoxin-free distilled water, sonicated, and stored at either
70°C or aliquoted and relyophilized to dryness.
Production of recombinant M. leprae proteins
The DNA sequences coding for the four novel M. leprae proteins
(ML0008, ML0126, ML1057, and ML2567) were amplified from M. lep-
rae genomic DNA using rTth DNA polymerase XL (Applied Biosystems).
PCR amplifications were performed using each of the following primer sets
designed to introduce NdeI or NheI and XhoI or HindIII sites, respectively
(underlined), to the 5 and 3 ends of the open reading frame: for ML0008,
forward primer, 5-ACACATATGGCAACAATTAGAACGGTAA-3
(NdeI), and reverse primer, 5-ATAAGCTTTTTTGTGTATCGAAGA
CAGT-3 (HindIII); for ML0126, forward primer, 5-TCTCATATGA
GAGCAGCCGAAGCTTCGA-3 (NdeI), and reverse primer, 5-
CGTATCTCGAGAGGGTCGACCCGGGC-3 (XhoI); for ML1057, for-
ward primer, 5-AACATATGCAGAGGAGAACGAGATGGAT-3
(NdeI), and reverse primer, 5-ATGAAGCTTGCCTAAGTGGAGC
GATC-3 (HindIII); and for ML2567, forward primer, 5-
AAAGCTAGCGTGAGGCCGGGCGAGTTCC-3 (NheI), and reverse
primer, 5-GGCTAATAAGCTTGCCGCACATGCG-3 (HindIII). The
PCR products were digested with the restriction enzymes NdeI/NheI and
HindIII/XhoI and cloned into the expression vector pET 29a(), which
uses a T7 promoter-driven system to achieve high levels of recombinant
protein expression with a C-terminal 6-histidine tag. The DNA sequences
of recombinant clones were confirmed by automated nucleotide sequencing
(model 377; Applied Biosystems) at Macromolecular Resources Labora-
tory, Colorado State University. The plasmids containing the four novel
Ags were introduced into the Escherichia coli expression host BL21 (DE3)
(Invitrogen Life Technologies) by transformation. Recombinant proteins
were produced as soluble proteins as described previously (11). LPS
content, as measured by the limulus amoebocyte lysate test (BioWhittaker),
was found to be 2 ng/mg protein.
Abs and Western blot analysis
Polyclonal antisera against the recombinant proteins were raised in
BALB/c mice and used in immunoblotting as described previously (11).
Native M. leprae cytosol, membrane, and cell wall fractions were prepared
as described previously (12). Proteins (1–30 g) from each of the subcel-
lular fractions were separated on 15% SDS-PAGE and transferred to ni-
trocellulose membrane as previously described (13) for probing with Abs.
Human serum samples and ELISA
Serum samples from lepromatous (LL) leprosy patients were selected from
anonymous serum samples stored at the Department of Microbiology, Yon-
sei University College of Medicine. Approval of the use of these serum
samples was given by the internal review boards at Yonsei University
College of Medicine and Colorado State University and complied with
federal rules for their use.
Recombinant Ags were diluted to 1.0 mg/ml PBS (pH 7.2) and were
dispersed using a probe sonicator. Each Ag was then diluted further to 5
g/ml in carbonate-bicarbonate buffer (pH 9.6), and 100 l of the diluted
Ag was added to wells of 96-well flat-bottom EIA plates and kept over-
night at 4°C for coating. The ELISA to detect Abs in patient serum samples
was performed as described previously (11).
Preparation of cDNA from M. leprae RNA for quantitative RT-
PCR (qRT-PCR)
M. leprae strain Thai-53 was purified from infected nude mouse footpad
tissue using a previously described protocol (14). The RNA was purified
from 2  1010 bacteria or directly from the minced biopsy material using
a single-tube homogenization/RNA extraction protocol (15). Total M. lep-
rae RNA was converted to cDNA using the Advantage cDNA Polymerase
Mix and Advantage RT-for-PCR kit (BD Clontech) with random hexamers
according to the manufacturer’s recommendations. qRT-PCR assays for six
M. leprae genes, including groES (ML0380), encoding 10-kDa GroES;
bfrA (ML2038c), encoding bacterioferritin; and ML0008c, ML0126,
ML1057, and ML2567, encoding four unique hypothetical unknown pro-
teins, were developed using TaqMan technology. Primers and probes were
designed for qRT-PCR assays by acquiring gene sequences from the M.
leprae genome database (www.Sanger.ac.uk/Projects/M. leprae) and us-
ing Primer Express software (Applied Biosystems). All genes were ampli-
fied from the same M. leprae cDNA template. The qRT-PCR data was
analyzed using the relative quantitation method for gene expression based
on the appropriate standard curve and expressed as mean and SD.
Study population for cell-mediated assay
For the analysis of IFN- responses of M. leprae recombinant proteins and
peptides, a total of 60 volunteer subjects was enrolled, 10 in each group.
Untreated PB (10 borderline tuberculoid (BT) patients), and MB (3 LL and
7 borderline LL (BL) patients) leprosy patients, and household contacts
(HC) of MB patients were recruited from the Souza Araujo Outlet Unit,
Oswaldo Cruz Foundation. Untreated PPD skin test positive pulmonary TB
patients were recruited from the Clementino Fraga Filho Hospital, Federal
University of Rio de Janeiro. Healthy individuals living in Rio de Janeiro
and with an unknown history of exposure to leprosy and/or TB were in-
cluded as an endemic control (EC) group, while individuals living in the
state of Colorado served as the nonendemic control (NEC) group. The tests
and procedures described in this work were approved by the Oswaldo Cruz
Foundation Ethics Committee and the internal review board of Colorado
State University.
In vitro culture of PBMC with Ags
Blood was drawn by venipuncture, heparinized, and PBMC were isolated
using Lymphoprep (Pharmacia Biotech) by density gradient centrifugation,
washed in PBS, and resuspended in AIMV medium (Invitrogen Life Tech-
nologies) supplemented with 100 U/ml penicillin, 100 g/ml streptomycin,
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and 2 mM L-glutamine (Sigma-Aldrich). PBMC from each individual were
seeded at 2  105 cells/well in 96-well flat-bottom plates in duplicate (BD
Biosciences) and stimulated in vitro with armadillo-derived M. leprae
whole cells (20 g/ml), individual recombinant proteins or peptides (10
g/ml), or staphylococcal enterotoxin B (SEB; 1 g/ml) (Sigma-Aldrich).
Cultures were incubated at 37°C in a humidified 5% CO2 atmosphere.
Supernatants were harvested at day 5 of incubation and stored immediately
at 70°C until performing the cytokine ELISA. IFN- levels were assayed
in duplicate using the IFN- DuoSet ELISA Development System kit
(R&D Systems) with a detection limit of 125 pg/ml.
CD69 expression and IFN- intracellular staining
PBMC were seeded (5  105/well) in 96-well flat-bottom microtiter plates
in complete AIMV medium and were stimulated with single peptides (p51,
p52, p59, p61, p65, and p69) or a pool of these peptides in the presence of
costimulatory mAbs specific for CD28 and CD49d. The culture plates were
incubated in a humidified 37°C incubator for a total of 6h, with the last 1 h
including 10 g/ml brefeldin A (Sigma-Aldrich). After incubation the cells
were permeabilized, followed by fixation with 1% paraformaldehyde in
PBS. The cells were washed with wash buffer (0.5% BSA and 0.1% NaN3
in PBS) stained with 2 l of combined anti-IFN- FITC, anti-CD69 PE,
and anti-CD4 PerCP-Cy5.5 (BD Pharmingen) or 20 l of combined anti-
IFN- FITC, anti-CD69 PE, anti-CD8 PerCP-Cy5.5, and anti-CD3 APC
(BD Pharmingen). Control tubes were stained as above but with
isotype-matched mAbs.
Flow cytometric analysis
Four-color flow cytometric acquisition and analysis were performed on a
FACSCalibur flow cytometer using BD CellQuest Pro software (BD Bio-
sciences). Forty thousand CD4 T cells and 10,000 CD8 T cells were
collected typically. The cells were gated on CD4 and CD3/CD8 T
cells vs side-scattering to isolate CD4 T and CD8 T cells, then gated on
forward light-scattering vs side-scattering to analyze the lymphocyte pop-
ulation. Data were analyzed and displayed as dot plots of IFN- vs CD69
fluorescence. A negative region for each cell population was defined with
isotype control Abs. CaliBRITE beads (BD Pharmingen) were used for
setting photomultiplier tube voltages, fluorescence compensation, and in-
strument sensitivity before use.
Statistical analysis
ANOVA (Statistica, version 6.0; Statsoft) was performed to determine dif-
ferences in IFN- levels induced by each Ag among PB patients, MB
patients, HC individuals, TB patients, and EC individuals. In this analysis,
the cutoff was defined as twice the value of the detection limit (250 pg/ml).
This analysis was followed by the Tukey test used as a post hoc test for
two-group comparisons. Results between groups were considered signifi-
cant when p was 0.05.
Results
Identification of homologies of peptides and proteins in other
mycobacterial databases
The criteria for selecting many of the peptides from unique hypo-
thetical unknown proteins and other proteins of interest from M.
leprae was performed in early 2002. Since this study was initiated,
sequences from other mycobacterial genome projects have become
available, including the completed sequence of M. bovis (16) and
the nearly completed or preliminary sequences of the genomes of
M. avium, M. marinum, M. smegmatis, M. ulcerans, and M. para-
tuberculosis. The most recent search (August 25, 2005) using the
BLASTP program for short nearly exact matches identified addi-
tional homologies within the 58 peptides that were selected. Pep-
tide p55 from ML2567 (9-mer) showed 100% identity with an
8-mer from another gene in M. leprae, ML0314, a putative ester-
ase, although these proteins are not otherwise related. Peptides p62
from ML0678c (83% identity of a 12-mer in gene MAP3814c),
p86 and p87 from ML0840c (80% identity of a 10-mer peptide in
gene MAP2122 and 66% identity of a 15-mer in the same gene,
respectively), and p88 and p89 from ML1189c (84% identity of a
13-mer in gene MAP2344 and 80% identity of a 15-mer in the
same gene, respectively) all had relatively high identities with pep-
tides from M. avium paratuberculosis strain K10. Peptide p69
from ML1419c (9-mer) showed 100% identity with an 8-mer from
Streptomyces coelicolor. Peptides p79 from ML0098 ( fbpC) and
p93 from ML2591 (mce1C), which had homologues in M. tuber-
culosis and were selected to examine cross-reactive responses in
TB individuals, also showed high identity with peptide sequences
in M. avium paratuberculosis strain K10 (86% identity with a 15-
mer in fbcC1 and 93% identity with a 15-mer in gene MAP3606).
Table I. M. leprae peptides predicted to have high binding scores to
HLA MHC molecules and tested for IFN- responses in this studya
Peptide ID/Gene Location Sequence
p37 ML0008c aa 1–15 MATIRTVRNLKLCNP
p38* ML0008c aa 21–35 TRLLTVVVKQRSKAF
p39* ML0008c aa 24–38 LTVVVKQRSKAFRPS
p40* ML0008c aa 107–121 RVSYGSECRSGNCLR
p41 ML0008c aa 2–10 ATIRTVRNL
p42* ML0126 aa 250–264 LDDFLSLQRSISPNS
p43 ML0126 aa 90–104 ATHYFEMTSDAFFAD
p44* ML0126 aa 251–265 DDFLSLQRSISPNSY
p45 ML0126 aa 65–79 DVKIAVDPACKLSAR
p46 ML0394c aa 117–131 HLILRITPGIDLREL
p47* ML0394c aa 73–87 LNQLVSLVKQIFVQQ
p48* ML0394c aa 22–36 QLMYLIEITSETKAL
p49* ML1057 aa 10–24 GRYYAEINSAKMYFG
p50 ML1057 aa 46–60 VLVLVGDEAAALEQL
p51* ML1057 aa 54–68 AAALEQLLGQTADVA
p52* ML1057 aa 59–67 QLLGQTADV
p53* ML2567 aa 95–109 RRTVKILRPLPSNIT
p54* ML2567 aa 72–86 NHAVSSDFKTRSTNT
p55 ML2567 aa 128–136 DIAARLASL
p56* ML0308 aa 17–31 FDEYRAMFALSAMDL
p57 ML0308 aa 139–153 THAFDLVLSSHLLFT
p58 ML0308 aa 194–208 DDLLARLRADGVHGE
p59 ML0398c aa 15–29 MLILGLLPAILPACG
p60 ML0398c aa 288–302 AILYRKIHGQDPAER
p61* ML0398c aa 16–24 LILGLLPAI
p62 ML0678c aa 31–45 PYRFHSLAAIWALSP
p63* ML0757c aa 6–20 GINLPKDELTAFGRK
p64 ML0757c aa 74–88 VGAVRIVGGVRPQNF
p65* ML1419c aa 108–122 EAVLLRLDGTTLEVE
p66* ML1419c aa 137–151 QVIFRDLTTQKAAEE
p67* ML1419c aa 51–65 SGRVTYLNPVGVKWM
p68* ML1419c aa 267–275 LLEEGVIVL
p69* ML1419c aa 113–121 RLDGTTLEV
p70* ML1420 aa 93–107 MQEYRGLTSHTPCCR
p71* ML1553 proS aa 180–194 LDIYTTLARDMAAIP
p72 ML1553 proS aa 154–168 TIEFLWQEGHSAHIE
p73* ML1829 aa 108–122 DAEWLKLTSLGLRPR
p74* ML1915 aa 89–104 VKAVVDDVNAILLTGR
p75* ML2177c aa 169–183 LQPYRLLRGGDSEYW
p76* ML2498 aa 75–89 VGKVQGLLARLLTLP
p77* ML2703 trxB aa 331–335 DSTDTTDWSTAMTDA
p78 ML0411 aa 264–278 GLDSIISSASASLLT
p79 ML0098 fbpC aa 84–98 GNAMTTLGGRGISVV
p80* ML0126 aa 125–139 YGQVVRDVENTLRYL
p81* ML0126 aa 180–194 GDVWKSIVHLRSTRH
p82* ML0394c aa 141–155 KKRLTLLSGAMARRA
p83* ML0394c aa 97–111 DATFQVIFSQHVHLS
p84 ML0638 aa 1–15 MIDYNNVFGAGVVAA
p85 ML0638 aa 49–63 NYEVSPIFARWPRNR
p86* ML0840c aa 287–301 VYLYNYLLAETSHVL
p87 ML0840c aa 251–265 YRYYRLIATTDAASP
p88* ML1189c aa 55–69 DDIWRTLASAVITGN
p89 ML1189c aa 10–24 FDSFDRILKARSPEA
p90 ML2347 aa 20–34 KENVIIVAAKISWTL
p91* ML2347 aa 301–315 LATVQYDDRRRFTKE
p92* ML2452c aa 28–42 LQAYSNLFGRTSAMQ
p93 ML2591 mce1C aa 62–76 GMDVGKVEALKIDGD
p94 ML2596 aa 165–179 WASVALLTAAGVSLG
a The information on all of the genes, sequences, and class was obtained from
www.genolist.pasteur.fr/Leproma/. Peptides that elicited responses in only the lep-
rosy patient or contact groups and not in the TB or EC groups appear with an asterisk;
bold indicates the peptide is from a hypothetical unknown protein (class VI).
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A search of homologies with the four hypothetical unknown genes
in this study found that although ML0008, ML1057, and ML2567
did not have orthologues in M. tuberculosis or other currently
available mycobacterial databases, a gene with 69% identity to
ML0126 was identified in the M. ulcerans genome (http://geno-
pole.pasteur.fr/Mulc/Burulist.html). The six 15-mer peptides from
ML0126 (p42–p45, p80, and p81) that were tested in our study
showed between 67 and 87% identity with predicted sequences in
M. ulcerans. As more sequences are added to mycobacterial da-
tabases, other orthologues and homologues to the class VI hypo-
thetical unknown proteins of M. leprae may be identified.
IFN- responses of PBMC toward recombinant proteins and
peptides
The list of the synthetic peptides and the genes from which they
were selected is shown in Table I. PBMC from leprosy patient
groups (PB and MB), leprosy HC, TB patient, healthy EC, and
healthy NEC groups were cultured with recombinant proteins, pep-
tides and control Ags, and IFN- production was measured on day
5 of culture. The results for the IFN- responses to four of the
recombinant proteins and controls are shown in Fig. 1, while rep-
resentative responses to a subset of the 58 peptides is shown in Fig.
2. Responses to all of the leprosy peptides and protein Ags in the
NEC group were uniformly negative, while IFN- responses were
below or, in a few cases, just above the detection limit, in all
unstimulated cultures (medium alone) for all groups. All individ-
uals responded well when their cells were cultured in the presence
of the superantigen SEB. The responses to the four recombinant
proteins were generally higher than with individual peptides, with
more responses in the EC and TB groups (ML0008, 6 EC and 2 TB
responders; ML0126, 9 EC and 2 TB responders; ML1057, 10 EC
and 1 TB responders; ML2567, 7 EC and no TB responders) (Fig.
1). The responses of PBMC from Brazilian leprosy patients and
contact individuals toward most of the peptides showed remark-
able specificity, stimulating IFN- production in 60–100% of the
10 BT patients (PB group) and 50–100% of the 10 subjects in the
HC group. Between 1–4 of 10 individuals in the MB group re-
sponded to certain peptides. Thirty-five of the peptides showed no
positive responses in the TB or EC groups, and good responses in
the PB and HC groups (peptides indicated by an asterisk in Table
I), while 23 of the peptides showed one or more heightened IFN-
responses in either the TB or EC groups. A few of the peptides that
elicited the most frequent responses in the EC or TB groups were
those that had homologues in M. tuberculosis, such as peptides p79
( fbpD homologue Rv3803c, 80% identity), p93 (mce1C homo-
logue Rv0171, 73% identity), and p72 ( proS homologue Rv2845c,
27% identity). Other peptides that induced responses in the EC or
TB groups had very low or no discernible homology with their
counterpart in M. tuberculosis, such as peptides p57 and p60. A
few of the peptides from several hypothetical unknowns, with no
homologue to any gene in mycobacterial databases, induced un-
expected responses in the EC or TB groups, such as p37 from
ML0008. It may be that cross-reactive epitopes within these pep-
tides will be revealed as more mycobacterial sequences are added
to the database.
An analysis of the original data indicated that certain individuals
in the PB group responded well to the majority of the peptides,
while other individuals responded weakly or not at all to many of
the peptides; those in the TB and EC group were nonresponsive to
almost all of the peptides (Fig. 3). The best responders in these
groups also reacted well to the M. leprae whole cell Ag prepara-
tion. Generally, members of the HC group responded as well as, or
better than, individuals in the PB group, which was expected be-
cause most HC, although having been exposed to the disease for
varying amounts of time, are healthy but immune, so their T cell
responses to M. leprae Ags are quite robust. In summary, the re-
sponses in the leprosy patients, contacts, and controls to the ma-
jority of peptides were quite specific, showing none of the cross-
reactivity that has been reported with whole recombinant proteins
that have low homology (17, 18).
Four of the six 9-mers showed good potential specificity. Three
of these six 9-mer peptides were contained within one of the tested
15-mer peptides: p52 within p51 (ML1057), p61 within p59
(ML0398c), and p69 within p65 (ML1419c). For the pairs of pep-
tides from ML1057 and ML1419c, both the longer 15-mer peptide
and the shorter 9-mer peptide were specific, inducing good re-
sponses in the PB and HC groups, and no response in the TB, EC,
or NEC groups; for the peptides from ML0398c, the shorter 9-mer
peptide appeared more specific than the longer 15-mer peptide.
Overall, 31 of 52 of the 15-mer peptides gave promising specific-
ity, while 4 of 6 of the 9-mer peptides did. This indicates that
shorter 9-mer peptides, which would be expected to induce Ag-
specific CD8 activation, as well as longer peptides that would be
mainly recognized by CD4 T cells, have diagnostic potential.
FIGURE 1. IFN- responses of PBMC from PB and MB leprosy patients, HC, TB patients, and healthy EC and NEC to the four M. leprae recombinant
hypothetical unknown proteins (ML0008, ML0126, ML1057, and ML2567), M. leprae whole cells, and the superantigen SEB. Medium alone (unstimu-
lated) represents IFN- responses in the absence of antigenic stimulus. The dashed line represents the cutoff of 125 pg/ml IFN- measured in the culture
supernatants. The number of total responders appears below each group.
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Frequency of CD69 and IFN--producing CD4 and CD8 T
cells to 9- and 15-mer peptides
To define the phenotype of T cells responding to the 15- and 9-mer
peptides, the frequencies of peptide-specific IFN--producing
CD4 and CD8 T cells present in the blood from a BT patient
were analyzed by flow cytometry. The results show elevated fre-
quencies of IFN--producing CD4 and CD8 T cells that were
induced after stimulating with either single 15- or 9-mer peptides
or a mixture of the same peptides. When 9-mers and 9-mer-con-
taining 15-mers were compared, the 9-mer peptides preferentially
activated CD8 T cells, while the 15-mer peptides induced re-
sponses in both CD4 and CD8 T cell subsets (Fig. 4). This
observation is in agreement with previous data, indicating that 15-
mer peptides are effective for the activation of both CD4 and
CD8 T cells (19).
Statistical analysis of responses of the groups to individual
peptides
The levels of IFN- induced by individual peptides in the different
groups of subjects were compared for statistical significance using
ANOVA. In addition to the ANOVA test, the Tukey test was used
as a post hoc test for evaluating significant differences between two
groups. When individually analyzed, three types of responses
could be distinguished, represented in Fig. 5 by peptides p67, p69,
and p75. The plots display the mean values for each group, and the
0.95 confidence intervals were adjusted using least squares for
ANOVA modeling. IFN- responses to p69 were significantly
higher in HC ( p 	 0.02) and in PB ( p 	 0.01) in comparison with
those seen in MB and control groups (TB and EC). Twenty-nine of
the 35 peptides that showed no positive responses in the TB and
EC groups induced this type of response and can be potentially
FIGURE 2. Representative IFN- responses of PBMC from PB and MB leprosy patients, HC, TB patients, and healthy EC and NEC to peptides comprising
a subset of the 58 peptides tested. Twenty peptides induced responses in the PB and HC groups, with no responses in either the TB or EC groups. Peptides p57,
p60, p72, and p79 were peptides that induced responses in multiple individuals in the TB and EC groups in addition to responses in the PB and HC groups. The
dashed line represents the cutoff of 125 pg/ml IFN- measured in the culture supernatants. The number of total responders appears below each group.
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used to detect both HC and PB. Peptide p75, in contrast, induced
significantly higher levels of IFN- in HC as compared with PB
( p 	 0.04) and MB ( p 	 0.001) and control groups ( p 	 0.001).
Three other peptides (p68, p91, and p92) induced the same type of
response and can potentially be used to distinguish healthy in-
fected individuals. Finally, IFN- responses to p67 were signifi-
cantly higher in PB ( p 	 0.01) as compared with HC ( p 	 0.04)
and to those seen in MB ( p 	 0.01) and control groups ( p 	 0.01)
and show diagnostic potential for PB leprosy.
Expression and serological reactivity toward hypothetical
unknown proteins
Polyclonal antisera raised against the four hypothetical unknown
proteins were used to probe the native subcellular fractions for the
presence of these Ags. However, within the limits of sensitivity of
this approach, there was no detectable signal found for any of these
proteins by immunoblot (data not shown). We then designed
probes and primers for the four hypothetical unknowns and two
well-expressed proteins, ML0380 (groES) and ML2038c (bfrA), in
an attempt to understand the relationship between the cDNA tran-
script levels and protein expression. ML0008c (the lowest ex-
pressed transcript, assigned the arbitrary value of 1.00) was used as
the calibrator to obtain the relative expression values of the other
genes; therefore, values are expressed as fold increase expression
over ML0008c. The results demonstrated that of the six gene tran-
scripts analyzed using mouse footpad M. leprae mRNA, the most
highly represented cDNA was that of ML0380, followed by
ML2038c (Table II), data which are consistent with their relative
abundance as expressed proteins. The ML0126 transcript level was
2-fold higher than ML0008c, but caution should be used in in-
terpreting whether this result indicates whether there is a similar
fold increase in relative protein expression, as the value was so
low. Unknown proteins ML2567 and ML1057 showed consider-
ably higher values at 5.20 and 8.83, respectively. The same relative
expression of these genes was observed from cDNA obtained from
both nude mouse footpad derived M. leprae and from M. leprae
obtained from human biopsy material (data not shown).
The reactivity of leprosy patient sera toward the hypothetical
proteins was examined by ELISA. The majority of LL patient sera
reacted well to both ML0050 (10-kDa culture filtrate protein (CFP-
10)) and fusion proteins (CFP-10/early secreted antigenic target, 6
kDa (ESAT-6) and 10 kDa/ESAT-6), whereas the responses to the
hypothetical proteins showed much lower responses overall (Fig.
6). This result probably reflects the very low levels of expression
of these proteins as detected by Western blot analysis. Alterna-
tively, the lack of Ab recognition of these E. coli-produced recom-
binant proteins could be the result of improper folding, as three of
them contain multiple cysteines that could potentially be involved
in disulfide linkages (ML0008, ML0126, and ML2567). Neverthe-
less, there were more positive responses against ML2567 and
ML1057 than with ML0008 or ML0126, which is consistent with
the higher gene transcript levels found with these proteins.
Discussion
Diagnostic tests based on cell-mediated immune responses against
M. leprae have been studied because it was determined that intra-
dermal inoculation of a heat-killed extract of M. leprae, called
lepromin, induced characteristic responses in individuals infected
with the disease (20, 21). A number of laboratories have examined
the antigenic makeup of the M. leprae ever since a reliable source
FIGURE 3. Individual IFN- responses from the
PB, TB, and EC groups against the four recombinant
proteins and their respective peptides and the peptides
from ML0394 and against whole M. leprae. u indicates
the relative amounts of IFN- detected;, 125 pg/ml
(less than detection limit cutoff); o, 125–299 pg/ml; z,
300–499 pg/ml; dark gray, 500–999 pg/ml; f, 
1000
pg/ml.
7935The Journal of Immunology
 at Y
onsei M
edical Library on July 1, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
of purified whole cells first became available through the growth of
M. leprae in the armadillo in the 1970s (22, 23). We have char-
acterized a number of the dominant Ags found in each of the three
main subcellular fractions (cytosol, membrane and soluble cell
wall proteins), which include the major cytosolic proteins, major
membrane proteins, and major cell wall Ags (12, 24, 25). A recent
analysis of the cytosolic and membrane proteins by two-dimen-
sional gels, with a characterization of tryptic-digested protein spots
by tandem mass spectrometry, MALDI-TOF, and N-terminal se-
quencing, revealed a total of 43 proteins that had not been iden-
tified previously (26). Despite doubling the number of known pro-
teins, virtually all of them have counterparts in M. tuberculosis that
have very high homology. Although these and many other com-
mon Ags have been shown to be highly immunogenic, their in-
clusion in the native crude subcellular fractions would certainly
lead to cross-reactive immune responses. Thus, the incorporation
of native subcellular fractions in a skin test or in vitro IFN- assay
with patient whole blood or PBMC may not have the requisite
specificity, similar to experiences with PPD as a predictor of ex-
posure to TB in countries where TB and leprosy are endemic and
exposure to nonpathogenic mycobacteria in the soil and water
is high.
To circumvent this problem, our laboratory has begun to focus
on Ags that have either less homology to their counterparts in M.
tuberculosis or have been shown to be unique to the M. leprae
genome. IFN- secretion in the culture supernatants was used as
the readout for the T cell response because it has been shown that
Table II. Relative transcript expression levels of four hypothetical
unknown proteins and two well-expressed proteins (ML0380 (10-kDa
GroES) and ML2038c (bacterioferritin)) as determined by TaqMan
RT-PCR analysis of nude mouse footpad-derived M. lepraea
Transcript/Gene Name Relative Expression
ML0008c 1.00
ML0126 2.08
ML2567 5.20
ML1057 8.83
ML2038c bfrA 17.52
ML0380 groES 36.68
a ML0008c was assigned the value of 1.00, while the relative expression of the
other transcripts was calculated based on this reading.
FIGURE 4. Peripheral ex vivo frequencies of peptide-specific IFN-
producing CD4 and CD8 T cells in a BT leprosy patient. PBMC were
stimulated with single peptides (p51, p52, p59, p61, p65, and p69 at 10g/
ml) and a mixture of peptides (10 g/ml each). Six hours later, the cells
were stained using the FastImmune CD4 (anti-IFN- FITC, anti-CD69 PE,
and anti-CD4 PerCp-Cy5.5) or CD8 (anti-IFN- FITC, anti-CD69 PE, anti-
CD3-APC, and anti-CD8 PerCp-Cy5.5) intracellular cytokine detection
kits. The analysis was performed on lymphocytes after gating on CD4 T
cells (40,000 events) and CD8 T cells (10,000 events) in a FACSCalibur
flow cytometer. A, Dot plots show the frequency of p51- and p52-respond-
ing IFN--producing CD69/CD4 T and CD69/CD8 T cells. B, The
histogram bars show the frequencies of IFN--producing CD69/CD4
and CD69/CD8 T cells responding to the 9-mer peptides p52, p61, and
p69 and to the 9-mer-containing 15-mer peptides p51, p59, and p65, re-
spectively, and to a mixture of these six peptides.
FIGURE 5. ANOVA of IFN- levels induced by M. leprae synthetic
peptides. The vertical bars denote 0.95 confidence intervals. Values of p
were as follows: p67, p 	 0.00003; p69, p 	 0.00003; and p75, p 	
0.00008. The Tukey test was used as a post hoc test for evaluating the
significant difference between groups, and the p values 0.05 are indicated
in the graphics. PB, PB leprosy patients; MB, MB leprosy patients; TB, TB
patients; and EC, healthy EC.
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protective immunity to mycobacterial infection requires the spe-
cific activation of T cells secreting type 1 cytokines, such as IFN-
(27, 28). Initially, we predicted that due to the comparatively low
amounts of message and lack of positive results in detecting these
hypothetical unknown proteins by Western blot analysis, T cell
responses would be correspondingly low. The surprising finding is
that not only are there positive responses in the majority of the PB
and HC groups to all four of the whole recombinant proteins tested
but that there are also positive responses with almost all of the
peptides from these same proteins. There were higher average
amounts of IFN- produced in all groups to the whole proteins, but
there were also many more positive responses in the EC and TB
groups, indicating that, as with the case with ESAT-6 and CFP-10,
there may be cross-reactive epitopes present. However, the re-
sponses to the majority of the peptides (35 of 58, or 60%) were
remarkably specific, inducing positive responses only in the PB
and HC groups and no responses (or in rare cases, just above the
detection limit of 125 pg/ml IFN-) in any of the control groups.
An interesting observation was the diagnostic potential of a num-
ber of the peptides (p67, p68, p75, p91, and p92) in terms of their
capacity to discriminate among the known M. leprae-infected in-
dividuals (PB patients) and exposed but healthy individuals who
have not yet developed any symptoms of the disease (HC group).
It is possible that the detection of responses in the HC group and
not PB or MB individuals are the result of latency-associated Ags,
similar to that which has been found in healthy individuals infected
with M. tuberculosis. Further study of these peptides using a much
larger group size will be required to determine whether this rela-
tionship holds.
There have been a number of recent studies that have evaluated
T cell responses of TB patients and BCG-vaccinated individuals
toward recombinant proteins and peptides derived from genes
found in regions of difference (designated regions RD1 to RD16),
regions of the genome that are present in virulent strains of M.
tuberculosis and M. bovis, but which are absent in all or most of
the BCG vaccine strains (29, 30). These studies have identified
ESAT-6 and CFP-10, two of the most intensely studied Ags, both
of which have shown great potential for TB diagnosis (31, 32), and
for the detection of latent TB infection (33). The use of combina-
tions of peptides from these two Ags provided a high level of
sensitivity and specificity in IFN- T cell assays (34, 35). A num-
ber of other potential TB-specific peptide Ag candidates have been
identified from these RD region genes, and some of these have
been examined for sensitivity and specificity by themselves and in
combination with ESAT-6 and CFP-10 proteins (36–38). Al-
though some peptides from the RD1 PPE protein Rv3873 were
shown to be cross-reactive in nature due to the high homology with
peptides from conserved regions in other members of the PPE
family, others were shown to be very specific (36). Similarly, the
findings in our present study that there were more frequent re-
sponses in the EC and TB groups to the whole recombinant pro-
teins is perhaps an indication of possible cross-reactive responses
toward peptides that show homology to as yet unidentified pep-
tides from other mycobacteria, even though three of four whole
proteins examined were supposedly “unique” to M. leprae. Other
studies have shown fewer problems with cross-reactivity using
peptides compared with using the whole protein, so this may be
one way to avoid undesirable cross-reactivity by selecting only
those peptides that stimulate responses in the targeted group
(38, 39).
Our observation that IFN- responses were detected to both
shorter 9-mer peptides and to longer 15-mer peptides may also
have important implications. The fact that we detected M. leprae-
specific responses to both shorter 9-mer peptide and 15-mer pep-
tides that contained the shorter 9-mer peptides indicate that such
15-mer peptides might show greater sensitivity, as both Ag-spe-
cific CD4 and CD8 T cells are activated by such sequences. The
recent observation that, contrasting with CD8 T cells, the CD4
T cell population requires the presence of Ag for proliferation even
in the course of an inflammatory response, supports the evaluation
of the frequency of CD4 T cells specific for M. leprae Ags as a
tool for detecting active and latent M. leprae infection (40). Al-
though it was harder to select suitable 9-mer peptides for testing,
as shorter sequences tended to show greater homologies to se-
quences in other genes, the specific responses detected here to four
of the six 9-mer peptides tested indicates that Ag-specific CD8 T
cell responses are also present and may have diagnostic potential.
A recent BLASTP search for short nearly exact matches with our
panel of peptides revealed homologies with sequences in recently
added mycobacterial databases. Although this new information ap-
pears to affect a minority of peptides, further testing will be re-
quired to determine whether some of these candidates should be
eliminated from the pool due to problems with cross-reactivity.
To design a diagnostic test that is both highly sensitive and
specific for leprosy, it is likely that multiple Ags or peptides will
have to be incorporated as a mixture or as a polyprotein because it
has been shown that the use of multiple Ags increases the fre-
quency of responses in infected individuals. Factors that influence
the response to individual components of an Ag mixture include
the genetic makeup (due to MHC polymorphisms) of the individ-
ual and whether a given peptide can be presented by that person’s
MHC molecules; the immune status of the individual, who may be
nonresponsive due to HIV infection or disease induced anergy; and
the variation of the T cell response to particular Ags during the
course of infection, which is probably very important for those
with tuberculoid vs LL forms of the disease. Currently, we are
examining the responses of larger numbers of leprosy patients and
controls with pooled peptides, in the hope to increase the overall
response in the PB and HC groups, and perhaps even increase the
percentage of responders in the MB group, while retaining a high
level of specificity. It is important to remember that in the context
of an endemic country, examining the responses in the healthy
FIGURE 6. Reactivity of leprosy patient sera by ELISA to the novel M.
leprae recombinant proteins ML0008, ML1057, ML0126, and ML2567
compared with other proteins known to be expressed at higher levels
ESAT-6 (ML0049), CFP-10 (ML0050), and 10 kDa (ML0380). Two of the
proteins tested are fusion proteins consisting of 10 kDa/ESAT-6 and CFP-
10/ESAT-6. N values in boxes represent the number of individual sera that
gave negative OD readings.
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endemic control population is the most relevant. It should be pos-
sible to combine a number of these peptides to formulate a highly
sensitive and specific cell-mediated test that will allow the early
and rapid diagnosis of leprosy.
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